KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.85

Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy.

Yu-Ling Hsu, Chun-Hui Lee, Wei-Pang Chung, Wen-Huang Lee, Kuo-Ting Lee, Jui-Hung Tsai, Hui-Ping Hsu, Shuen-Ru Yang, Zhu-Jun Loh, Pei-Fang Su, Chao-Ming Hung, Wei-Chuan Tsai, Yen-Wen Liu, Ping-Yen Liu

Eur J Heart Fail 27(11) 2141-2151

PMID40637120
PMCID-
DOI10.1002/ejhf.3758
发表日期2025-07-10
入排依据:The study is a randomized Phase III trial with a drug intervention and a clinical efficacy endpoint, but the endpoint (incidence of CTRCD) is not a time-to-event outcome as required for this cohort. It is a cardioprotective study, not an oncology efficacy trial.
入排复审未纳入:The study is a randomized Phase III trial with a drug intervention and a clinical efficacy endpoint, but the endpoint (incidence of CTRCD) is not a time-to-event outcome as required for this cohort. It is a cardioprotective study, not an oncology efficacy trial.
摘要

摘要

AIMS: Cancer therapy-related cardiac dysfunction (CTRCD) can adversely affect clinical outcomes in patients with cancer. The cardioprotective effects of sacubitril/valsartan in preventing CTRCD remain underexplored. This study aimed to evaluate the cardioprotective effects of sacubitril/valsartan in preventing CTRCD in patients with early breast cancer during the first year after adjuvant therapy. METHODS AND RESULTS: One hundred newly diagnosed treatment-naïve patients with early breast cancer (50.4 ± 8.5 years, 98% women) were enrolled prospectively between May 2021 and July 2023. Participants were randomized at a 1:4 ratio to receive sacubitril/valsartan, starting 3 days before cancer therapy at an initial dose of 12.25/12.75 mg twice daily, titrated to a maximum dose of 24.5/25.5 mg twice daily (n = 20), or standard care with monitoring and initiation of standard therapies upon CTRCD occurrence (n = 80) for 12 months. There were no significant differences in the baseline demographic characteristics between the two groups. The mean doxorubicin-equivalent dose was 276.0 ± 48.5 mg/m2 in the sacubitril/valsartan group and 269.5 ± 57.9 mg/m2 in the standard care group (p = 0.175). The primary endpoint was the development of CTRCD, defined as a relative ≥15% decline in global longitudinal strain (GLS) or a reduction in left ventricular ejection fraction by ≥10 percentage points to below 50%. Of the 100 randomized patients, 95 (95%) completed the trial. No patient in the sacubitril/valsartan group developed CTRCD, whereas 21 patients (26.3%) in the standard care group did (p = 0.006). All events of CTRCD were identified based on significant decline in GLS. CONCLUSIONS: Low-dose sacubitril/valsartan may prevent CTRCD in treatment-naïve patients with early breast cancer undergoing adjuvant therapy within the first year. Large phase III clinical trials are needed to confirm these findings.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。